OPTUM®

Quick reference interactive drug guide

What you need to know to get your patients started on prescribed oncology drugs.

Trying to find the right information to prescribe the right therapies can be overwhelming when specialty drugs are constantly being developed and approved. To make things easier, we've created an interactive oncology drug reference guide containing some of the top drugs across multiple indications. Keep this guide handy to access the information you need all in one place.

Commonly prescribed specialty drugs in cancer care

Breast cancer	Prostate cancer	Ovarian cancer
Xeloda (capecitabine)	Xtandi (enzalutamide)	Lynparza (olaparib)
Ibrance (palbociclib)	Zytiga (abiraterone)	Zejula (niraparib)
Verzenio (abemaciclib)	Lynparza (olaparib)	Rubraca (rucaparib)
Lynparza (olaparib)	Erleada (apalutamide)	Alkeran (melphalan)
Afinitor (everolimus)	Nubeqa (darolutamide)	

Colorectal cancer	Lung cancer	Blood cancer
Xeloda (capecitabine)	Tagrisso (osimertinib)	Revlimid (lenalidomide)
Stivarga (regorafenib)	Mekinist (trametinib)	Imbruvica (ibrutinib)
Braftovi (encorafenib)	Tafinlar (dabrafenib)	Pomalyst (pomalidomide)
Lonsurf (trifluridine and tipracil)	Alecensa (alectinib)	Gleevec (imatinib)
	Tarceva (erlotinib)	Venclexta (venetoclax)

Renal cancer	Liver cancer	Skin cancer
Cabometyx (cabozantinib)	Cabometyx (cabozantinib)	Mekinist (trametinib)
Afinitor (everolimus)	Stivarga (regorafenib)	Tafinlar (dabrafenib)
Inlyta (axitinib)	Lenvima (lenvatinib)	Erivedge (vismodegib)
Lenvima (lenvatinib)	Nexavar (sorafenib)	Braftovi (encorafenib)
Votrient (pazopanib)		Mektovi (binimetinib)

As you use this list of commonly prescribed drugs, you may have questions about certain aspects of prescribing or the patient's treatment plan. Visit our **website** for information or resources, or to get in touch with one of our account managers.

Breast Cancer	Pharmacologic Category	FDA-label Indications Back to table
Xeloda (capecitabine)	Antimetabolite	Breast cancer, metastatic Colorectal cancer
Ibrance (palbociclib)	Cyclin-dependent kinase inhibitor	Breast cancer, advanced (initial endocrine-based therapy) Breast cancer, advanced (with disease progression following endocrine therapy)
Verzenio (abemaciclib)	Cyclin-dependent kinase inhibitor	Breast cancer, advanced or metastatic Breast cancer, early, high risk
Lynparza (olaparib)	PARP inhibitor	Breast cancer, metastatic (BRCA-mutated, HER2-negative) Ovarian cancer, advanced, refractory (BRCA-mutated) Ovarian cancer, advanced (BRCA-mutated), first-line maintenance therapy Ovarian cancer, advanced (homologous recombination deficient-positive), first-line maintenance thearpy Ovarian cancer, recurrent (maintenance therapy) Pancreatic cancer, metastatic (BRCA-mutated), first-line maintenance therapy Prostate cancer, metastatic, castration-resistant (homologous recombination repair gene-mutated)
Afinitor (everolimus)	mTOR kinase inhibitor	Breast cancer, advanced Neuroendocrine tumors Renal call carcinoma, advanced Tuberous sclerosis complex-associated partial-onset seizures Tuberous sclerosis complex-associated renal angiomyolipoma Tuberous sclerosis complex-associated subependymal giant cell astrocytoma

Prostate Cancer	Pharmacologic Category	FDA-label Indications Back to table
Xtandi (enzalutamide)	Anti-androgen	Prostate cancer
Zytiga (abiraterone)	Anti-androgen	Prostate cancer, metastatic
Lynparza (olaparib)	PARP inhibitor	Breast cancer, metastatic (BRCA-mutated, HER2-negative) Ovarian cancer, advanced, refractory (BRCA-mutated) Ovarian cancer, advanced (BRCA-mutated), first-line maintenance therapy Ovarian cancer, advanced (homologous recombination deficient-positive), first-line maintenance thearpy Ovarian cancer, recurrent (maintenance therapy) Pancreatic cancer, metastatic (BRCA-mutated), first-line maintenance therapy Prostate cancer, metastatic, castration-resistant (homologous recombination repair gene-mutated)
Erleada (apalutamide)	Anti-androgen	Prostate cancer
Nubeqa (darolutamide)	Anti-androgen	Prostate cancer, nonmetastatic, castration-resistant

Ovarian Cancer	Pharmacologic Category	FDA-label Indications Back to table
Lynparza (olaparib)	PARP inhibitor	Breast cancer, metastatic (BRCA-mutated, HER2-negative) Ovarian cancer, advanced, refractory (BRCA-mutated) Ovarian cancer, advanced (BRCA-mutated), first-line maintenance therapy Ovarian cancer, advanced (homologous recombination deficient-positive), first-line maintenance thearpy Ovarian cancer, recurrent (maintenance therapy) Pancreatic cancer, metastatic (BRCA-mutated), first-line maintenance therapy Prostate cancer, metastatic, castration-resistant (homologous recombination repair gene-mutated)
Zejula (niraparib)	PARP inhibitor	Ovarian, fallopian tube, or primary peritoneal cancer
Rubraca (rucaparib)	PARP inhibitor	Ovarian cancer, advanced (BRCA-mutated) Ovarian cancer, recurrent (maintenance) Prostate cancer, metastatic, castration-resistant (BRCA-mutated)
Alkeran (melphalan)	Alkylating agent	Multiple myeloma Ovarian cancer, palliative, nonresectable

Colorectal Cancer	Pharmacologic Category	FDA-label Indications Back to table
Xeloda (capecitabine)	Antimetabolite	Breast cancer, metastatic Colorectal cancer
Stivarga (regorafenib)	Tyrosine kinase inhibitor, VEGF inhibitor	Colorectal cancer, metastatic GI stromal tumors Hepatocellular carcinoma
Braftovi (encorafenib)	BRAF kinase inhibitor	Colorectal cancer, metastatic Melanoma, unresectable or metastatic
Lonsurf (trifluridine and tipracil)	Antimetabolite; thymidine phosphorylation inhibitor	Colorectal cancer, metastatic Gastric cancer, metastatic

Lung Cancer	Pharmacologic Category	FDA-label Indications Back to table
Tagrisso (osimertinib)	Tyrosine kinase inhibitor, EGFR inhibitor	Non-small cell lung cancer, adjuvant therapy Non-small cell lung cancer, metastatic
Mekinist (trametinib)	MEK inhibitor	Melanoma Non-small cell lung cancer, metastatic Thyroid cancer, anaplastic, locally advanced or metastatic
Tafinlar (dabrafenib)	BRAF kinase inhibitor	Melanoma Non-small cell lung cancer, metastatic Thyroid cancer, anaplastic, locally advanced or metastatic
Alecensa (alectinib)	Tyrosine kinase inhibitor	Non-small cell lung cancer, metastatic (ALK-positive)
Tarceva (erlotinib)	Tyrosine kinase inhibitor, EGFR inhibitor	Non-small cell lung cancer, metastatic Pancreatic cancer, locally advanced, unresectable or metastatic

Blood Cancers	Pharmacologic Category	FDA-label Indications Back to table
Revlimid (lenalidomide)	Angiogenesis inhibitor	Follicular lymphoma (previously treated) Mantle cell lymphoma (relapsed or progressive) Marginal zone lymphoma (previously treated) Multiple Myeloma Myelodysplastic syndromes
Imbruvica (ibrutinib)	Bruton tyrosine kinase inhibitor	Chornic graft-versus-host disease (refractory) Chronic lymphocytic leukemia/small lymphocytic lymphoma Mantle cell lymphoma, previously treated Marginal zone lymphoma, relapsed/refractory Waldenstrom macroglobulinemia
Pomalyst (pomalidomide)	Angiogenesis inhibitor	Kaposi sarcoma Multiple myeloma, relapsed/refractory
Gleevec (imatinib)	BCR-ABL tyrosine kinase inhibitor	Acute lymphoblastic leukemia Aggressive systemic macrocytosis Chronic myeloid leukemia Dermatofibrosarcoma protuberans Gastrointestinal stromal tumors Hypereosinophilic syndrome and/or chronic eosinophilic leukemia Myelodysplastic/Myeloproliferative diseases
Venclexta (venetoclax)	BCL-2 inhibitor	Acute myeloid leukemia Chronic lymphocytic leukemia/small lymphocytic lymphoma

Renal Cancer	Pharmacologic Category	FDA-label Indications Back to table
Cabometyx (cabozantinib)	Tyrosine kinase inhibitor, VEGF inhibitor	Hepatoceullar carcinoma, advanced Renal cell carcinoma, advanced Thyroid cancer, differentiated, locally advanced or metastatic
Afinitor (everolimus)	mTOR kinase inhibitor	Breast cancer, advanced Neuroendocrine tumors Renal call carcinoma, advanced Tuberous sclerosis complex-associated partial-onset seizures Tuberous sclerosis complex-associated renal angiomyolipoma Tuberous sclerosis complex-associated subependymal giant cell astrocytoma
Inlyta (axitinib)	Tyrosine kinase inhibitor, VEGF inhibitor	Renal cell carcinoma, advanced
Lenvima (lenvatinib)	Tyrosine kinase inhibitor, VEGF inhibitor	Endometrial carcinoma, advanced Hepatocellular carcinoma, unresectable Renal cell carcinoma, advanced Thyroid cancer, differentiated
Votrient (pazopanib)	Tyrosine kinase inhibitor, VEGF inhibitor	Renal cell carcinoma, advanced Soft tissue sarcoma, advanced

Liver Cancer	Pharmacologic Category	FDA-label Indications Back to table
Cabometyx (cabozantinib)	Tyrosine kinase inhibitor, VEGF inhibitor	Hepatocellular carcinoma, advanced Renal cell carcinoma, advanced Thyroid cancer, differentiated, locally advanced or metastatic
Stivarga (regorafenib)	Tyrosine kinase inhibitor, VEGF inhibitor	Colorectal cancer, metastatic GI stromal tumors Hepatocellular carcinoma
Lenvima (lenvatinib)	Tyrosine kinase inhibitor, VEGF inhibitor	Endometrial carcinoma, advanced Hepatocellular carcinoma, unresectable Renal cell carcinoma, advanced Thyroid cancer, differentiated
Nexavar (sorafenib)	Tyrosine kinase inhibitor, VEGF inhibitor	Hepatocellular carcinoma Renal cell carcinoma Thryoid carcinoma, differentiated

Skin Cancer	Pharmacologic Category	FDA-label Indications Back to table
Mekinist (trametinib)	MEK inhibitor	Melanoma Non-small cell lung cancer, metastatic Thyroid cancer, anaplastic, locally advanced or metastatic
Tafinlar (dabrafenib)	BRAF kinase inhibitor	Melanoma Non-small cell lung cancer, metastatic Thyroid cancer, anaplastic, locally advanced or metastatic
Erivedge (vismodegib)	Ovaria	Basal cell carcinoma, metastatic or locally advanced
Braftovi (encorafenib)	BRAF kinase inhibitor	Colorectal cancer, metastatic Melanoma, unresectable or metastatic
Mektovi (binimetinib)	MEK inhibitor	Melanoma, unresectable or metastatic

Optum Specialty Pharmacy, Rx volume, Oncology Cateogry, 1.1.21-12.20.21, ranked by patient count

Lexicomp. Drug information. UpToDate. Retrieved December 1, 2021



optum.com

11000 Optum Circle, Eden Prairie, MN 55344

Optum is a leading health services innovation company dedicated to helping make the health system work better for everyone. With more than 160,000 people collaborating worldwide, Optum combines technology, data and expertise to improve the delivery, quality and efficiency of health care.

All Optum trademarks and logos are owned by Optum, Inc. All other trademarks are the property of their respective owners.

© 2022 Optum, Inc. All rights reserved. OPT6730026_220310